Ballentine Partners, LLC Rocket Pharmaceuticals, Inc. Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 88,570 shares of RCKT stock, worth $270,138. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,570Holding current value
$270,138% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RCKT
# of Institutions
194Shares Held
96.4MCall Options Held
563KPut Options Held
418K-
Rtw Investments, LP New York, NY17.7MShares$53.9 Million0.77% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx8.47MShares$25.8 Million0.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.89MShares$21 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$18.9 Million0.0% of portfolio
-
Bio Impact Capital LLC Cambridge, MA3.9MShares$11.9 Million2.3% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $231M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...